The Tisch Cancer Institute at The Mount Sinai Health System


“Best Hospitals” cancer-care score: 50.7/100

Founded: 2007

Beds: 1,031

Clinicians/researchers: 186




Research focus: 

Genomics and molecular pathology.


Clinic at-a-glance:

Tisch Cancer Institute has long been at the forefront of breakthroughs in diagnosing and treating cancer. This center was the first to link cigarettes and asbestos to cancer, and the first to chemically induce cancer cells to return to normal patterns of development. It utilizes leading-edge diagnostic technologies including computed tomography, positron emission tomography, and CT-guided bronchoscopy. It also emphasizes minimally invasive treatment procedures such as laparoscopy and stereotactic radiosurgery. Patients have access to many clinical trials, some to test the effectiveness of introducing genes that cause cancer cells to self-destruct and others to test whether the body’s immune system can be strengthened to better fight the cancer. Among Tisch’s ongoing research studies are those investigating various aspects of mesothelioma, ranging from molecular research to treatment protocols. Tisch provides extensive resources for patients and their families, including opportunities to participate in support groups, obtain advice, receive coordinated counseling, benefit from expert nursing care, and access educational services, all in a supportive environment.